Sutro Biopharma (STRO) Net Margin (2017 - 2025)
Sutro Biopharma (STRO) has disclosed Net Margin for 9 consecutive years, with 2188.14% as the latest value for Q4 2025.
- Quarterly Net Margin rose 115731.0% to 2188.14% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 12.52% through Dec 2025, up 1689.0% year-over-year, with the annual reading at 0.09% for FY2025, 390.0% up from the prior year.
- Net Margin hit 2188.14% in Q4 2025 for Sutro Biopharma, up from 586.58% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 2188.14% in Q4 2025 to a low of 1146.05% in Q1 2025.
- Historically, Net Margin has averaged 148.06% across 5 years, with a median of 324.53% in 2021.
- Biggest YoY gain for Net Margin was 115731bps in 2025; the steepest drop was -69854bps in 2025.
- Year by year, Net Margin stood at 357.85% in 2021, then fell by -12bps to 400.76% in 2022, then surged by 107bps to 27.31% in 2023, then soared by 3675bps to 1030.83% in 2024, then skyrocketed by 112bps to 2188.14% in 2025.
- Business Quant data shows Net Margin for STRO at 2188.14% in Q4 2025, 586.58% in Q3 2025, and 18.04% in Q2 2025.